Medical technology company Inspire Medical Systems (NYSE: INSP) will be reporting earnings this Monday after market close. Here’s what to expect.

Inspire Medical Systems beat analysts’ revenue expectations by 1.2% last quarter, reporting revenues of $217.1 million, up 10.8% year on year. It was a softer quarter for the company, with full-year revenue guidance missing analysts’ expectations significantly and a significant miss of analysts’ full-year EPS guidance estimates.

Is Inspire Medical Systems a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Inspire Medical Systems’s revenue to grow 8.4% year on year to $220.2 million, slowing from the 32.5% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.17 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Inspire Medical Systems has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 1.6% on average.

Looking at Inspire Medical Systems’s peers in the healthcare equipment and supplies segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Bausch + Lomb delivered year-on-year revenue growth of 7.1%, meeting analysts’ expectations, and Integer Holdings reported revenues up 8.4%, in line with consensus estimates. Bausch + Lomb’s stock price was unchanged after the resultswhile Integer Holdings was down 33.3%.

Read our full analysis of Bausch + Lomb’s results here and Integer Holdings’s results here.

Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Inspire Medical Systems is down 5.3% during the same time and is heading into earnings with an average analyst price target of $117.40 (compared to the current share price of $72.50).

P.S. STOP buying the AI stocks everyone’s talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.